Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Full application, invited only)
Funding Amounts: Up to $200,000 total over 2 years; max $100,000/year; includes direct costs and up to 5% indirect costs.
Summary: Supports translational and clinical research to improve quality of life or mitigate side effects for people living with metastatic breast cancer.
Key Information: Patient advocate involvement is required at all stages of application and research.